AstraZeneca's MedImmune subsidiary has entered a clinical trial collaboration with US biotechnology company Advaxis aimed at boosting the companies' distinct investigational cancer immunotherapies by administering them together.
The Phase I/II immunotherapy study will evaluate AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?